Abstract 183P
Background
Personalized targeted cancer treatment strongly depends on genetic tests in tumor tissue. Meanwhile, it is essential to understand the oncogenicity of a large number of somatic and germline variants to identify potential drug targets, which can be used for further treatment. An adopted classification scheme to guide variant oncogenicity assessment has to be easy, fast and reproducible. In this study we implemented a full-fledged database SomaVar and web-based frontend for somatic variant upload, annotation and classification using the VICC classification guidelines.
Methods
The frontend provides a multitude of utility functions which include an advanced variant search, user defined variant lists, automatic classification criteria selection and extensive administrative utilities. SomaVar supports variant annotation including in-silico pathogenicity prediction scores, splicing prediction scores, third party classifications, population scores and protein domains. SomaVar has a semi-automatic classification algorithm for oncogenicity based on the VICC standards and allows harmonized consensus classification between different users.
Results
Using a list of variants already classified by experts we show that the automatic classification algorithm provides a high-quality preselection for most VICC criteria. This not only increases the speed at which experts can classify variants, but also increases quality by mitigating human error. We also compared our knowledgebase to OnkoKB. A large overlap was found within the both groups of variants of likely oncogenic and of unclear oncogenicity variants. Interestingly, divergent classification was observed for variants located within splice regions and for benign variants listed in gnomAD at high allele frequencies.
Conclusions
To date, our knowledgebase harbors over 20.000 classified somatic variants and continues to grow. This open-source knowledgebase is publicly available online.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - Whole exome sequencing reveals high frequency of Notch pathway mutations in Indian breast cancer cases
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Abacavir potentiates the efficacy of doxorubicin in breast cancer cells via KDM5B Inhibition
Presenter: Anmi Jose
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - Identification of immune profile in advanced cutaneous squamous cell carcinoma predicting immunotherapy response
Presenter: Alfonso Esposito
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - MicroRNA as a promising molecular biomarker for liquid biopsy in breast cancer
Presenter: Giorgia Vesca
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - Patient-based models to study infiltration heterogeneity in gliomas
Presenter: Ivana Manini
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - HER2 aberration as a potential predictive biomarker for extrapulmonary small cell neuroendocrine carcinoma
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Assessment of methylation-specific genetic markers for reliable colorectal cancer detection and their potential in liquid biopsy applications
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Calculated numerical karyotype with ultra low-coverage whole genome sequencing undercovers recurrent chromosomal aberrations in resectable colorectal cancer
Presenter: Thomas Samer Tarawneh
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - Promising epi(genetic) biomarkers for ovarian tumor prognosis
Presenter: Ieva Vaicekauskaitė
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Integration of miRNA profiles and p53 mutations as biomarkers for predicting sensitivity and resistance to FGFR inhibitor CPL110 in cancer therapy
Presenter: Monika Skupinska
Session: Cocktail & Poster Display session
Resources:
Abstract